325 related articles for article (PubMed ID: 35033589)
21. Hormone-sensitive prostate cancer: a case of ETS gene fusion heterogeneity.
Attard G; Jameson C; Moreira J; Flohr P; Parker C; Dearnaley D; Cooper CS; de Bono JS
J Clin Pathol; 2009 Apr; 62(4):373-6. PubMed ID: 19066166
[TBL] [Abstract][Full Text] [Related]
22. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer.
Winnes M; Lissbrant E; Damber JE; Stenman G
Oncol Rep; 2007 May; 17(5):1033-6. PubMed ID: 17390040
[TBL] [Abstract][Full Text] [Related]
23. Novel RNA hybridization method for the in situ detection of ETV1, ETV4, and ETV5 gene fusions in prostate cancer.
Kunju LP; Carskadon S; Siddiqui J; Tomlins SA; Chinnaiyan AM; Palanisamy N
Appl Immunohistochem Mol Morphol; 2014 Sep; 22(8):e32-40. PubMed ID: 25203299
[TBL] [Abstract][Full Text] [Related]
24. Oncogenic ETS Factors in Prostate Cancer.
Nicholas TR; Strittmatter BG; Hollenhorst PC
Adv Exp Med Biol; 2019; 1210():409-436. PubMed ID: 31900919
[TBL] [Abstract][Full Text] [Related]
25. Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis.
Lunardi A; Varmeh S; Chen M; Taulli R; Guarnerio J; Ala U; Seitzer N; Ishikawa T; Carver BS; Hobbs RM; Quarantotti V; Ng C; Berger AH; Nardella C; Poliseno L; Montironi R; Castillo-Martin M; Cordon-Cardo C; Signoretti S; Pandolfi PP
Cancer Discov; 2015 May; 5(5):550-63. PubMed ID: 25653093
[TBL] [Abstract][Full Text] [Related]
26. Characterization of TMPRSS2:ETV5 and SLC45A3:ETV5 gene fusions in prostate cancer.
Helgeson BE; Tomlins SA; Shah N; Laxman B; Cao Q; Prensner JR; Cao X; Singla N; Montie JE; Varambally S; Mehra R; Chinnaiyan AM
Cancer Res; 2008 Jan; 68(1):73-80. PubMed ID: 18172298
[TBL] [Abstract][Full Text] [Related]
27. SLC45A3-ELK4 is a novel and frequent erythroblast transformation-specific fusion transcript in prostate cancer.
Rickman DS; Pflueger D; Moss B; VanDoren VE; Chen CX; de la Taille A; Kuefer R; Tewari AK; Setlur SR; Demichelis F; Rubin MA
Cancer Res; 2009 Apr; 69(7):2734-8. PubMed ID: 19293179
[TBL] [Abstract][Full Text] [Related]
28. Fusion between TMPRSS2 and ETS family members (ERG, ETV1, ETV4) in prostate cancers from northern China.
Wang JJ; Liu YX; Wang W; Yan W; Zheng YP; Qiao LD; Liu D; Chen S
Asian Pac J Cancer Prev; 2012; 13(10):4935-8. PubMed ID: 23244085
[TBL] [Abstract][Full Text] [Related]
29. ETV1, 4 and 5: an oncogenic subfamily of ETS transcription factors.
Oh S; Shin S; Janknecht R
Biochim Biophys Acta; 2012 Aug; 1826(1):1-12. PubMed ID: 22425584
[TBL] [Abstract][Full Text] [Related]
30. Molecular profiling of ETS gene rearrangements in patients with prostate cancer registered in REDEEM clinical trial.
Palanisamy N; Tsodikov A; Yan W; Suleman K; Rittmaster R; Lucia SM; Chinnaiyan AM; Fleshner N; Kunju LP
Urol Oncol; 2015 Mar; 33(3):108.e5-13. PubMed ID: 25175425
[TBL] [Abstract][Full Text] [Related]
31. [TMPRSS2-ETS gene fusion in prostate cancer].
Perner S; Schmidt FH; Hofer MD; Kuefer R; Rubin M
Urologe A; 2007 Jul; 46(7):754-60. PubMed ID: 17458530
[TBL] [Abstract][Full Text] [Related]
32. Truncated ERG proteins affect the aggressiveness of prostate cancer.
Wu F; Ding S; Lu J
Med Hypotheses; 2013 Apr; 80(4):490-3. PubMed ID: 23357671
[TBL] [Abstract][Full Text] [Related]
33. ETS transcription factors control transcription of EZH2 and epigenetic silencing of the tumor suppressor gene Nkx3.1 in prostate cancer.
Kunderfranco P; Mello-Grand M; Cangemi R; Pellini S; Mensah A; Albertini V; Malek A; Chiorino G; Catapano CV; Carbone GM
PLoS One; 2010 May; 5(5):e10547. PubMed ID: 20479932
[TBL] [Abstract][Full Text] [Related]
34. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming.
Iljin K; Wolf M; Edgren H; Gupta S; Kilpinen S; Skotheim RI; Peltola M; Smit F; Verhaegh G; Schalken J; Nees M; Kallioniemi O
Cancer Res; 2006 Nov; 66(21):10242-6. PubMed ID: 17079440
[TBL] [Abstract][Full Text] [Related]
35. Development of High-Throughput Screening Assays for Inhibitors of ETS Transcription Factors.
Currie SL; Warner SL; Vankayalapati H; Liu X; Sharma S; Bearss DJ; Graves BJ
SLAS Discov; 2019 Jan; 24(1):77-85. PubMed ID: 30204534
[TBL] [Abstract][Full Text] [Related]
36. Fusion in the ETS gene family and prostate cancer.
Narod SA; Seth A; Nam R
Br J Cancer; 2008 Sep; 99(6):847-51. PubMed ID: 18781147
[TBL] [Abstract][Full Text] [Related]
37. The peripheral zone of the prostate is more prone to tumor development than the transitional zone: is the ETS family the key?
Adler D; Lindstrot A; Ellinger J; Rogenhofer S; Buettner R; Perner S; Wernert N
Mol Med Rep; 2012 Feb; 5(2):313-6. PubMed ID: 22038307
[TBL] [Abstract][Full Text] [Related]
38. Molecular subtyping of primary prostate cancer reveals specific and shared target genes of different ETS rearrangements.
Paulo P; Ribeiro FR; Santos J; Mesquita D; Almeida M; Barros-Silva JD; Itkonen H; Henrique R; Jerónimo C; Sveen A; Mills IG; Skotheim RI; Lothe RA; Teixeira MR
Neoplasia; 2012 Jul; 14(7):600-11. PubMed ID: 22904677
[TBL] [Abstract][Full Text] [Related]
39. Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing.
Pflueger D; Terry S; Sboner A; Habegger L; Esgueva R; Lin PC; Svensson MA; Kitabayashi N; Moss BJ; MacDonald TY; Cao X; Barrette T; Tewari AK; Chee MS; Chinnaiyan AM; Rickman DS; Demichelis F; Gerstein MB; Rubin MA
Genome Res; 2011 Jan; 21(1):56-67. PubMed ID: 21036922
[TBL] [Abstract][Full Text] [Related]
40. ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells.
Zong Y; Xin L; Goldstein AS; Lawson DA; Teitell MA; Witte ON
Proc Natl Acad Sci U S A; 2009 Jul; 106(30):12465-70. PubMed ID: 19592505
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]